BUSINESS
F&O Manual: Traders expect some gains as day progresses
Global markets declined after the US Federal Reserve raised interest rates by 25 basis points, even as banking sector concerns weigh heavy
BUSINESS
CLSA's ratings upgrades trigger gains in life insurance stocks
Life insurance stocks have experienced a correction ranging from 7-24 percent since the budget.
BUSINESS
F&O Manual | Analysts foresee tepid trading as investors take cautious steps
A clear directional move in the market is unlikely before the release of the Federal Reserve's monetary policy decision, due later today.
BUSINESS
Dr Lal Pathlabs will sustain pre-COVID margins, says brokerage firm JM Financial
JM Financial foresees acquisitions coming in for Dr Lal Pathlabs in FY24 to drive inorganic growth as the company has sufficient net cash flows on its balancesheet.
BUSINESS
F&O Manual | Call writers pile up at 17,200, traders wait for a breakout
Traders expect upside momentum to catch up once the Nifty surpasses 17,150-17,200 zone.
BUSINESS
Brokerage firm Nirmal Bang sees favourable risk-reward in pharma
Pharma companies are likely to experience a recovery in margins, thanks to the easing of raw material costs and a reduction in price erosion in the US market.
BUSINESS
Divi's Labs set for big margin boost but valuations expensive, says MOFSL
The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company’s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said
BUSINESS
F&O Manual: Nifty slides, traders expect more weakness as day progresses
The Nifty snapped a two-day modest recovery as weak global cues dented sentiment. Most sectoral indices mirrored the Nifty and were trading low in the morning
BUSINESS
F&O Manual: Nifty gains but traders expect range-bound movement as day progresses
Buying from lower levels and positive global cues helped lift sentiment for domestic equities today.
BUSINESS
Why HDFC Securities is bullish on this smallcap pharma stock?
In November 2022, HDFC Securities initiated coverage on this pharma stock with a buy rating with a bull case target of Rs 66.60, which it achieved in January
BUSINESS
FTSE, S&P BSE's B-22 rebalance expected to attract $450m inflow
The rebalancing of FTSE's All World All Cap and S&P BSE's Bharat 22 indices will happen on March 17 and the changes will come into effect on March 20.
BUSINESS
IndusInd Bank shares tumble 3% post large deal
The stock has corrected around 13 percent in the past week.
BUSINESS
DLF shares zoom as realtor clocks in Rs 8,000 cr in pre-sales for Gurgaon luxury project
The real estate developer's residential business had also delivered 24 percent year-on-year growth in the third quarter.
BUSINESS
F&O Manual: Momentum to remain weak as volatility runs high
The Nifty is seen in a narrow range through the session as momentum remains weak.
BUSINESS
Channel checks by ICICI Securities reflect mixed price, volume trends for Specialty Chemcials cos in January
ICICI Securities has a "buy" rating on Gujarat Fluorochemicals, Archean Chemical, Tatva Chintan, EPL, Chemplast Sanmar, PCBL in the specialty chemicals basket, along with a "hold" call for industry leader SRF.
BUSINESS
Cipla shares gain as co to sell majority stake in Uganda subsidiary
With the stake sale, CQCIL will cease to be a subsidiary of Cipla.
BUSINESS
F&O manual | Some recovery is visible but traders suggest to wait for long addition
Most sectoral indices also traded in the green which suggests that recovery in the market is broad based.
BUSINESS
Know your stock | Is there a glimmer of hope for SeQuent Scientific?
The stock has witnessed a consistent decline since testing its record high in July 2021. Since then, the stock has plunged around 76% on the back of declining profits.
BUSINESS
Krsnaa Diagnostics shares soar on network expansion
The company is also preparing to open new centers in Uttar Pradesh, Delhi, Maharashtra, and Rajasthan.
BUSINESS
Analyst Call Tracker: Why do analysts favour Titan even as investors lose interest in the stock?
AK Prabhakar of IDBI Capital Markets & Securities says a slight correction in Titan's valuation towards Rs 2,000 can make it an excellent addition to investor portfolios
BUSINESS
Analyst Call Tracker: Why Dr Reddy's acquisition of Maynes Pharma failed to cheer analysts?
Buy calls slipped to 31 from 33 for Dr Reddy's Laboratories as ‘hold’ and ‘sell’ ratings climbed one each over February to a combined total of 11. The stock added a meagre 2 percent during the month.
BUSINESS
Analyst Call Tracker: Why three auto stocks are winning over analysts amid price volatility?
Bajaj Auto, Tata Motors and Mahindra & Mahindra were among 10 stocks with the maximum contrarian calls even as investors booked profits in them in February.
BUSINESS
SeQuent Scientific zooms 20% on terminating Tineta Pharma acquisition
The stock has corrected over 79.4 percent from its lifetime highs tested in July 2021.
BUSINESS
Navy Ramavat of Indira Securities predicts sustainable rebound for Nifty
Ramavat has expressed bullishness on several sectors, including capital goods, railways, PSU banks, and information technology. He sees potential for growth and investment opportunities in these sectors.
